NUVB
NYSE
$6.26
Nuvation Bio Inc - Class A (NUVB)
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. The company is headquartered in New York, New York.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $12.33 (+96.96%)
Market Cap
$2.04B
Free Cash Flow Yield
-6.15%
Beta (5Y)
1.47
Price Chart
Valuation
Market Cap$2.04B
P/S14.36
P/B6.43
Profitability
Total Revenue (TTM)$143M
Gross Profit (TTM)$130M
EBITDA-$148M
Profit Margin6.5%
Operating Margin4.7%
EPS-$0.43
Financial Health
Debt-to-Equity16.6%
Free Cash Flow Yield-6.15%
Growth & Risk
Beta (5Y)1.47
Sharpe Ratio1.54